ISB 2301 is a first-in-class candidate engineered to target three tumor-associated antigens while engaging both T cells and natural killer (NK) cells
Ichnos Glenmark Innovation, Inc. (IGI), a global clinical-stage biotechnology company, has submitted an Investigational New Drug (IND) application to the US Food and Drug Administration (FDA) for ISB 2301, an investigational pentaspecific immune cell activator designed to target solid tumors.
ISB 2301 is a first-in-class candidate engineered to target three tumor-associated antigens while engaging both T cells and natural killer (NK) cells.
The molecule combines five binding specificities, comprising three tumor-targeting components and two immune-cell activation components. By integrating tumor recognition with complementary immune-engaging mechanisms, the candidate is being developed to address the biological heterogeneity and immunosuppressive characteristics of solid tumors.
The molecule was developed using IGI’s proprietary BEAT Multispecific Platform. It is designed to activate immune responses through multiple mechanisms, including antibody-dependent cellular cytotoxicity (ADCC), checkpoint inhibition and the induction of a sustained type 1 immune response.
“Submission of the IND for ISB 2301 marks an important milestone in advancing IGI’s multispecific oncology pipeline into clinical development,” said Lida Pacaud, MD, President and Chief Executive Officer, IGI.
“This pentaspecific candidate is designed to integrate multiple tumor-targeting and immune-engaging functions within a single molecule. Our preclinical results have demonstrated a compelling anti-cancer profile for ISB 2301, a candidate we believe to be highly differentiated from current approaches. We plan to initiate a Phase I clinical trial of ISB 2301 in patients with solid tumors in 2027,” added Pacaud.
In preclinical studies, ISB 2301 demonstrated favourable pharmacokinetic and tolerability profiles in non-human primates. These findings support its planned clinical evaluation to assess safety, tolerability, pharmacokinetics, pharmacodynamics and anti-tumor activity in patients with advanced solid tumors.
The IND submission marks a significant step in advancing IGI's multispecific oncology research programme towards clinical development, with ISB 2301 representing the company's approach to combining multiple tumor-targeting and immune-activation capabilities within a single therapeutic molecule.
Subscribe To Our Newsletter & Stay Updated